Literature DB >> 14695119

Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules.

Catherine Lombry1, David A Edwards, Véronique Préat, Rita Vanbever.   

Abstract

We demonstrate that a primary source of elimination of inhaled macromolecules after delivery to the lungs and before absorption into the systemic circulation owes to clearance by alveolar macrophages (AM). Depletion of AM by liposome-encapsulated dichloromethylene diphosphonate is shown to cause severalfold enhancement in systemic absorption of IgG and human chorionic gonadotropin after intratracheal instillation in rats. Lowering the doses of IgG delivered to the lungs alleviates local degradation and results in a dramatic increase in systemic absorption of the protein as well. Chemical and physical means of minimizing uptake of macromolecules by AM are proposed as novel methods for enhancing protein absorption from the lungs. Such strategies may have important ramifications on the development of inhalation as an attractive mode of administration of therapeutic proteins to the bloodstream.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695119     DOI: 10.1152/ajplung.00260.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  13 in total

Review 1.  Immunotoxicological impact of occupational and environmental nanoparticles exposure: The influence of physical, chemical, and combined characteristics of the particles.

Authors:  Paola Pedata; Claudia Petrarca; Elpidio Maria Garzillo; Mario Di Gioacchino
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

2.  Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration.

Authors:  James P Cassidy; Nikhil Amin; Mark Marino; Mark Gotfried; Thomas Meyer; Knut Sommerer; Robert A Baughman
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

3.  Investigations into the fate of inhaled salmon calcitonin at the respiratory epithelial barrier.

Authors:  Leonie Baginski; Frederic Tewes; Stephen T Buckley; Anne Marie Healy; Udo Bakowsky; Carsten Ehrhardt
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

4.  Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery.

Authors:  Tammy W Shen; Catherine A Fromen; Marc P Kai; J Christopher Luft; Tojan B Rahhal; Gregory R Robbins; Joseph M DeSimone
Journal:  Pharm Res       Date:  2015-05-23       Impact factor: 4.200

5.  Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Eva Nozik-Grayck; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

6.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Authors:  Antoine Minne; Jamila Louahed; Sybille Mehauden; Benoît Baras; Jean-Christophe Renauld; Rita Vanbever
Journal:  Immunology       Date:  2007-05-22       Impact factor: 7.397

7.  Autocatalytic nitration of prostaglandin endoperoxide synthase-2 by nitrite inhibits prostanoid formation in rat alveolar macrophages.

Authors:  Stefan Schildknecht; Christiaan Karreman; Andreas Daiber; Cheng Zhao; Jürg Hamacher; David Perlman; Birgit Jung; Bernd van der Loo; Peter O'Connor; Marcel Leist; Volker Ullrich; Markus Michael Bachschmid
Journal:  Antioxid Redox Signal       Date:  2012-06-25       Impact factor: 8.401

Review 8.  Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.

Authors:  Caleb F Anderson; Maria E Grimmett; Christopher J Domalewski; Honggang Cui
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-10-10

Review 9.  Targeting inhaled therapy beyond the lungs.

Authors:  Ninell P Mortensen; Anthony J Hickey
Journal:  Respiration       Date:  2014       Impact factor: 3.966

Review 10.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

Authors:  Malgorzata Smola; Thierry Vandamme; Adam Sokolowski
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.